Semi-Annual Report — FY2026 H1
What Nxera Pharma Co.,Ltd. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-07View the original on EDINET
How much it says
66Detailed
What moved here
36named for the first time
Its own wording
36terms
Which filing this is
33/ 33newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, revenue increased year on year, and operating profit and interim profit turned from losses into profits. The filing also reports progress including the execution of an exclusive license agreement for vamorolone, Phase 3 topline results and a marketing application for daridorexant in South Korea, and Taiwan marketing approval for QUVIVIQ.
Komori's summary of this document, not the document's own words.66Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
68
Detailed
63
Detailed
38
Thin
0
Almost nothing
50
Typical
100
Very detailed
55
Typical
100
Very detailed
91
Very detailed
79
Very detailed
50
Typical
R&D spend60億円Money spent making new things.
Cash left over-4億円Cash from the business, less what went into equipment.
Spent on equipment4億円Plants, machines — things meant to last.
Employees322Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.